Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias

This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.

Inclusion Criteria:

• Patients with Parkinson's Disease
• Patients with L-dopa induced dyskinesia for at least 3 months
• Patients with L-dopa treatment for at least 3 years, stable for 1 month minimum

Exclusion Criteria:

• History of severe allergy to food or drugs
• Very low or high body weight.
• Prior surgery for Parkinson's Disease
• Smokers Other protocol-defined inclusion/exclusion criteria may apply